Cardiome Pharma Corp., a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, announced completion of enrollment for the Phase 4 SPECTRUM study evaluating Brinavess® (vernakalant hydrochloride, IV),...
Cardiome Pharma Corp., a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, announced completion of enrollment for the Phase 4 SPECTRUM study evaluating Brinavess® (vernakalant hydrochloride, IV),...
Cardiome Pharma Corp., a...